ATYR übertreffen die 28 der letzten 40Schätzungen.
70%
Nächster Bericht
Datum des nächsten Berichts
11. März 2026
Estimate forQ4 25(Revenue/ EPS)
$34.00K
/
-$0.19
Implizierte Änderung vonQ3 25(Revenue/ EPS)
-82.11%
/
-26.92%
Implizierte Änderung vonQ4 24(Revenue/ EPS)
--
/
+5.56%
aTyr Pharma, Inc. Common Stock earnings per share and revenue
On 06. Nov. 2025, ATYR reported earnings of -0.26 USD per share (EPS) for Q3 25, missing the estimate of -0.18 USD, resulting in a -38.81% surprise. Revenue reached 190.00 tausend, compared to an expected 1.36 million, with a -86.03% difference. The market reacted with a +6.05% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 12 analysts forecast an EPS of -0.19 USD, with revenue projected to reach 34.00 tausend USD, implying an decrease of -26.92% EPS, and decrease of -82.11% in Revenue from the last quarter.
FAQ
What were aTyr Pharma, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, aTyr Pharma, Inc. Common Stock reported EPS of -$0.26, missing estimates by -38.81%, and revenue of $190.00K, -86.03% below expectations.
How did the market react to aTyr Pharma, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 6.05%, changed from $0.77 before the earnings release to $0.82 the day after.
When is aTyr Pharma, Inc. Common Stock expected to report next?
The next earning report is scheduled for 11. März 2026.
What are the forecasts for aTyr Pharma, Inc. Common Stock's next earnings report?
Based on 12
analysts, aTyr Pharma, Inc. Common Stock is expected to report EPS of -$0.19 and revenue of $34.00K for Q4 2025.